Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13813: Variant p.Arg19Trp

Spectrin alpha chain, non-erythrocytic 1
Gene: SPTAN1
Feedback?
Variant information Variant position: help 19 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Tryptophan (W) at position 19 (R19W, p.Arg19Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In SPG91; pathogenic. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 19 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2472 The length of the canonical sequence.
Location on the sequence: help MDPSGVKVLETAEDIQER R QQVLDRYHRFKELSTLRRQK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         MDPSGVKVLETAEDIQERRQQVLDRYHRFKELSTLRRQK

Mouse                         MDPSGVKVLETAEDIQERRQQVLDRYHRFKELSTLRRQK

Rat                           MDPSGVKVLETAEDIQERRQQVLDRYHRFKELSTLRRQK

Chicken                       MDPSGVKVLETAEDIQERRQQVLDRYHRFKELSSLRRQK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 2472 Spectrin alpha chain, non-erythrocytic 1
Modified residue 1 – 1 N-acetylmethionine
Helix 14 – 25



Literature citations
De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia.
Van de Vondel L.; De Winter J.; Beijer D.; Coarelli G.; Wayand M.; Palvadeau R.; Pauly M.G.; Klein K.; Rautenberg M.; Guillot-Noel L.; Deconinck T.; Vural A.; Ertan S.; Dogu O.; Uysal H.; Brankovic V.; Herzog R.; Brice A.; Durr A.; Klebe S.; Stock F.; Bischoff A.T.; Rattay T.W.; Sobrido M.J.; De Michele G.; De Jonghe P.; Klopstock T.; Lohmann K.; Zanni G.; Santorelli F.M.; Timmerman V.; Haack T.B.; Zuechner S.; Schuele R.; Stevanin G.; Synofzik M.; Basak A.N.; Baets J.;
Mov. Disord. 37:1175-1186(2022)
Cited for: VARIANTS SPG91 TRP-19; CYS-1098; CYS-1619 AND LYS-2078 DEL; INVOLVEMENT IN SPG91;
Expanding SPTAN1 monoallelic variant associated disorders: From epileptic encephalopathy to pure spastic paraplegia and ataxia.
Morsy H.; Benkirane M.; Cali E.; Rocca C.; Zhelcheska K.; Cipriani V.; Galanaki E.; Maroofian R.; Efthymiou S.; Murphy D.; O'Driscoll M.; Suri M.; Banka S.; Clayton-Smith J.; Wright T.; Redman M.; Bassetti J.A.; Nizon M.; Cogne B.; Jamra R.A.; Bartolomaeus T.; Heruth M.; Krey I.; Gburek-Augustat J.; Wieczorek D.; Gattermann F.; Mcentagart M.; Goldenberg A.; Guyant-Marechal L.; Garcia-Moreno H.; Giunti P.; Chabrol B.; Bacrot S.; Buissonniere R.; Magry V.; Gowda V.K.; Srinivasan V.M.; Melegh B.; Szabo A.; Suemegi K.; Cossee M.; Ziff M.; Butterfield R.; Hunt D.; Bird-Lieberman G.; Hanna M.; Koenig M.; Stankewich M.; Vandrovcova J.; Houlden H.;
Genet. Med. 25:76-89(2023)
Cited for: VARIANTS SPG91 TRP-19; CYS-2119 AND PHE-2443; VARIANTS DEVEP 376-TRP--ASN-2472 DEL; 627-ARG--ASN-2472 DEL; 733-ARG--ASN-2472 DEL; TRP-1464; 1641-GLN--ASN-2472 DEL AND GLN-2199; VARIANTS DEE5 LYS-2078 DEL; GLU-2202 DEL; LYS-2266 AND ASP-GLN-LEU-2300 INS; INVOLVEMENT IN SPG91; INVOLVEMENT IN DEVEP; INVOLVEMENT IN DEE5;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.